There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .
Prevention of blood transfusion with intravenous iron in gynecologic cancer patients receiving platinum-based chemotherapy.
OBJECTIVES To compare the efficacy of intravenous iron and oral iron for prevention of blood transfusions in gynecologic cancer patients receiving platinum-based chemotherapy . MATERIAL S AND METHODS Sixty-four non anemic gynecologic cancer patients receiving adjuvant platinum-based chemotherapy were stratified and r and omized according to baseline hemoglobin levels and chemotherapy regimen . The study group received 200 mg of intravenous iron sucrose immediately after each chemotherapy infusion . The control group received oral ferrous fumarate at a dose of 200 mg three times a day . Complete blood count was monitored before each chemotherapy infusion . Blood transfusions were given if hemoglobin level was below 10mg/dl . RESULTS There were 32 patients in each group . No significant differences in baseline hemoglobin levels and baseline characteristics were demonstrated between both groups . Nine patients ( 28.1 % ) in the study group and 18 patients ( 56.3 % ) in the control group required blood transfusion through 6 cycles of chemotherapy ( p=0.02 ) . Fewer median number of total packed red cell units were required in the study group compared to the control group ( 0 and 0.5 unit , respectively , p=0.04 ) . Serious adverse events and hypersensitivity reactions were not reported . However , constipation was significantly higher in the control group ( 3.1 % and 40.6 % , p=<0.001 ) . CONCLUSIONS Intravenous iron is an effective , well-tolerated treatment for primary prevention of blood transfusions in gynecologic cancer patients receiving platinum-based chemotherapy , associated with less constipation than the oral formulation
There was no increased risk of infections with IV iron .
Gastrointestinal AEs were reduced with IV iron .
CONCLUSION Intravenous iron therapy is not associated with an increased risk of SAEs or infections .
Infusion reactions are more pronounced with IV iron
OBJECTIVE To amass all available evidence regarding the safety of intravenous ( IV ) iron preparations to provide a true balance of efficacy and safety .